Premium
P1‐063: CYANIDIN‐3‐GLUCOSIDE RICH BLACK RICE EXTRACT AND COGNITIVE FUNCTION IN SUBJECTIVE COGNITIVE IMPAIRMENT OLDER ADULTS: A DOUBLE‐BLIND, PLACEBO‐CONTROLLED, RANDOMIZED CLINICAL TRIAL
Author(s) -
Joo Soo hyun,
Hahn Changtae,
Lim Hyun Kook,
Lee Chang Uk
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.06.065
Subject(s) - placebo , cognition , randomized controlled trial , cognitive decline , repeated measures design , neuropsychology , dementia , cognitive test , effects of sleep deprivation on cognitive performance , medicine , psychology , psychiatry , disease , statistics , alternative medicine , mathematics , pathology
Background: The memory clinic at the Danish Dementia Research Centre has been reporting data to a quality registry since 2006. During that time period some of the cholinesterase-inhibitors (ChEI) and memantine have become generic. Generic donepezil was introduced in Demark Q1 of 2012. The aim of this abstract is to assess the prescription pattern of anti-dementia drugs over this time period in a tertiary referral center.Methods: Data from 2006 to 2017 on the use of anti-dementia drugs at the time of evaluation/diagnosis for patients diagnosed with Alzheimer’s disease, Mixed dementia (Alzheimer + Vascular), Dementia with Lewy Bodies, and Parkinson’s disease dementia was drawn from the clinical quality registry at the memory clinic at the Danish Dementia Research Centre. The 2017 data cleaning cutoff is Feb/18/2018, thus 2017-data may change. Persons referred for genetic counselling are excluded. Results: Of 8473 new referrals, 2619 patients (31% of all new referrals) were diagnosed with the relevant diagnosis (AD, Mixed dementia, DLB, PDD) (Table 1). Around the year 2012, the percentage of non-treated subjects dropped from approximately 25% to around 12%. At the same time the donepezil percentage of ChEI’s increased from 50-60% to approximately 95%. Conclusions: The data indicates that it had a major impact on the prescription practice, when donepezil became generic in 2012. The data only includes newly diagnosed patients with primarily mild dementia where memantine is off-label and only rarely used in Denmark.